Using miRNA and Gene Expression Profiling for Biomarker Discovery

In this presentation we will breakdown the fundamental motions and biomechanics of the shoulder. After discussing the biomechanics of the shoulder, we will explore epidemiology research regarding the risk of shoulder injuries.

Genomic analyses are yielding a host of new information on the multiple genetic abnormalities associated with specific types of cancer. A comprehensive description of cancer-associated genetic abnormalities can improve our ability to classify tumors into clinically relevant subgroups and sometimes identify drivers. However, the functional significance of cancer-associated mutations is often difficult to discern. Forward genetic screens provide a powerful tool to identify genes or genetic networks that contribute to specific biological phenotypes or diseases and therefore hold great potential for elucidating gene function and revealing therapeutic targets for diseases. The advent of CRISPR-Cas technology has revolutionized genome editing in higher eukaryotes and enables efficient gene manipulation in mammalian cells. CRISPR guide-RNA libraries allow facile generation of a pool of genetically perturbed cells and its application in genetic screens has marked a major breakthrough for functional genomics in mammalian cells.

Mapping the epigenetic and transcription factor landscape is essential for understanding gene regulatory mechanisms and holds huge potential for identification of biomarkers and targets for epigenetic therapy.

Monoclonal antibody-based therapeutics are well established in the pipelines of biopharmaceutical organizations and have decades of development ahead. However, not all of them have disclosed or confirmed amino acid sequences. Ultra-high-performance liquid chromatography mass spectrometry provides a powerful tool to obtain the sequence information to the residue level. Historically, the process has needed expert users and therefore was extremely low throughput and is often outsourced.